<DOC>
	<DOCNO>NCT00072904</DOCNO>
	<brief_summary>To recruit 150 adult patient cystic fibrosis relate diabetes ( CFRD ) without fast hyperglycemia multi-center , twelve month , placebo-controlled intervention trial test ability insulin repaglinide improve body mass index ( BMI ) stabilize pulmonary function cystic fibrosis ( CF ) .</brief_summary>
	<brief_title>Diabetes Therapy Improve BMI Lung Function CF</brief_title>
	<detailed_description>The primary objective research determine whether treatment either insulin oral diabetes agent increase endogenous insulin secretion improve BMI pulmonary function cystic fibrosis patient diabetes without fast hyperglycemia .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diabetic glucose pattern oral glucose tolerance test ( OGTT ) &gt; 200 120 min . ( stable healthy time OGTT ) Fasting glucose level &lt; 126 . Weight stable within 5 % previous 3 month . Free illness two month . Male female 16 old , do grow Willing come visit every 3 month . Patients receive infrequent short burst systemic glucocorticoid may consider study inclusion : a. receive systemic glucocorticoid steroids least one month , b. receive steroid 14 consecutive day 28 day total six month</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Cystic Fibrosis Related Diabetes</keyword>
	<keyword>Diabetes without Fasting Hyperglycemia</keyword>
</DOC>